Molecular characteristics of advanced colorectal cancer and multi-hit <i>PIK3CA</i> mutations
Multi-hit mutations in PIK3CA are seen in 1.7% of advanced CRC, a meaningful prevalence given the high burden of CRC worldwide, and may represent a subset of patients that have enhanced sensitivity to PI3K inhibition. Future investigation regarding the clinical utility of PI3K inhibitors is warranted in multi-hit PIK3CA CRC.
Authors
- Lajos Pusztai (ORCID: https://orcid.org/0000-0001-9632-6686)
- Ethan Sokol (ORCID: https://orcid.org/0000-0002-5480-8473)
- Mia Levy (ORCID: https://orcid.org/0000-0002-5944-2730)
- Dean C. Pavlick (ORCID: https://orcid.org/0000-0001-6075-6246)
- Richard S.P. Huang (ORCID: https://orcid.org/0000-0001-8395-5168)
- Faiza Yasin (ORCID: https://orcid.org/0000-0003-3042-0826)
- Jill Lacy (ORCID: https://orcid.org/0000-0002-2297-8435)
- Michael Cecchini (ORCID: https://orcid.org/0000-0003-3504-0128)
- Jeffrey S. Ross (ORCID: https://orcid.org/0000-0001-5865-6828)
- Neil Vasan (ORCID: https://orcid.org/0000-0003-1779-484X)
- Janie Yue Zhang
- Maureen Pelletier
Institutions
- SUNY Upstate Medical University (US)
- Boston Foundation (US)
- Yale Cancer Center (US)
- Yale University (US)
- New York Oncology Hematology (US)
- University of Pittsburgh Medical Center (US)
- Foundation Medicine (United States)
- Columbia University (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-10-14
- DOI
- https://doi.org/10.1093/oncolo/oyae259
- Citations
- 5
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.17